InO is the only ADC FDA-approved for the treatment of BCP-ALL (in adults); in contrast, CD19-targeting ADCs have shown promise in B-NHL but have not demonstrated sufficient efficacy in BCP-ALL (17). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.